Skip to content
Q1 '26Q4 '25Q3 '25Q2 '25Q1 '25
$149.39M-2.1%$152.61M+2.8%$148.39M+1.2%$146.56M+3.6%$141.42M-0.3%
$14.48M-44.5%$26.07M+15.1%$22.65M+9.9%$20.61M+15.1%$17.91M-17.2%
$134.92M+6.6%$126.54M+0.6%$125.74M-0.2%$125.95M+2.0%$123.51M+2.8%
90.3%+7.4pp82.9%-1.8pp84.7%-1.2pp85.9%-1.4pp87.3%+2.6pp
$2.66M+47.3%$1.81M-32.0%$2.66M-39.0%$4.36M+12.1%$3.89M+2.3%
$49.32M-7.7%$53.42M+12.5%$47.47M+3.3%$45.95M-2.1%$46.91M+6.2%
$73.23M+18.4%$61.85M-6.7%$66.27M0.0%$66.3M+4.6%$63.37M+0.8%
49%+8.5pp40.5%-4.1pp44.7%-0.6pp45.2%+0.4pp44.8%+0.5pp
$11M+9.4%$10.06M+111%$4.77M+59.2%$3M-62.2%$7.92M-30.2%
$84.23M+17.1%$71.9M+1.2%$71.04M+2.5%$69.29M-2.8%$71.29M-3.9%
$20.5M+6.7%$19.2M+5.2%$18.25M+6.2%$17.19M+18.1%$14.55M-20.3%
$63.73M+20.9%$52.7M-0.2%$52.78M+1.3%$52.11M-8.2%$56.74M+1.4%
42.7%+8.1pp34.5%-1.0pp35.6%0.0pp35.6%-4.6pp40.1%+0.7pp
$0.50+22.0%$0.41-2.4%$0.42+2.4%$0.41-8.9%$0.45+2.3%
$83.01M+16.3%$71.38M-5.7%$75.68M-0.1%$75.76M+4.0%$72.83M+0.7%
55.6%+8.8pp46.8%-4.2pp51%-0.7pp51.7%+0.2pp51.5%+0.5pp
$73.23M+18.4%$61.85M-6.7%$66.27M0.0%$66.3M+4.6%$63.37M+0.8%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

What is Catalyst Pharmaceutical's revenue?
Catalyst Pharmaceutical (CPRX) generated $597.0M in revenue over the trailing twelve months, up 11.7% year over year.
Is Catalyst Pharmaceutical profitable?
Catalyst Pharmaceutical reported $221.3M in net income over the trailing twelve months, a 37.1% net margin.
What are Catalyst Pharmaceutical's profit margins?
Gross margin is 86.0% and operating margin is 44.8%, with a 37.1% net margin.
What is Catalyst Pharmaceutical's earnings per share?
Catalyst Pharmaceutical's diluted EPS over the trailing twelve months is $1.74.
Where does Catalyst Pharmaceutical's income statement data come from?
Every line is extracted from Catalyst Pharmaceutical's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.